Cytovation_Logo_Twitter-02-res.png
Cytovation appoints Iman Barilero as Chief Development Officer
21 mars 2023 04h00 HE | Cytovation
Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that...
Statkraft inviterer
Statkraft inviterer nye eiere til den rasktvoksende ladevirksomheten Mer
13 mars 2023 03h00 HE | Statkraft AS
(Oslo, 13. mars 2023) Statkraft, Europas største produsent av fornybar energi, vurderer muligheter for å invitere inn nye eiere i det heleide ladeselskapet Mer, for å støtte selskapets ambisiøse...
Statkraft explores o
Statkraft explores opportunities for its fast-growing EV charging business Mer
13 mars 2023 03h00 HE | Statkraft AS
(Oslo, March 13 2023) Statkraft, Europe’s largest generator of renewable energy, has started to explore the opportunity to invite new shareholders into the ownership structure of its fully-owned...
Statkraft og Elkem signerer kraftavtale
Statkraft og Elkem signerer ny langsiktig kraftavtale i Midt-Norge
28 févr. 2023 09h00 HE | Statkraft AS
(Oslo, 28. februar 2023) Elkem og Statkraft har signert en ny langsiktig kraftavtale som sikrer Elkems anlegg i Bremanger ytterligere krafttilgang på konkurransedyktige vilkår. Avtalen omfatter en...
Signing PPA Elkem Statkraft
Statkraft and Elkem sign new competitive long-term power agreement in mid-Norway
28 févr. 2023 09h00 HE | Statkraft AS
(Oslo, 28. February 2023) Elkem and Statkraft have signed a new long-term power agreement which secures additional competitive access to power for Elkem’s plant in Bremanger. The new contract covers a...
Cytovation_Logo_Twitter-02-res.png
Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
15 févr. 2023 03h00 HE | Cytovation
Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces...
Oversiktsbilde av INEOS INOVYNs fabrikkanlegg på Rafnes
Statkraft og INEOS Inovyn inngår nye kraftavtaler - sikrer drift og legger til rette for nye investeringer
03 févr. 2023 08h00 HE | Statkraft AS
(Oslo/Rafnes, 3. februar 2023) Statkraft og kjemiselskapet INEOS Inovyn på Rafnes i Bamble har signert to nye, langsiktige kraftavtaler. Avtalene sikrer mesteparten av kraften som trengs til...
Overview of INEOS INOVYN Norway's facility at Rafnes
Statkraft and INEOS Inovyn sign new long-term green power agreements ensuring operations and enabling new investments
03 févr. 2023 08h00 HE | Statkraft AS
(Oslo/Rafnes, Norway, 3 February 2023) Europe’s largest generator of renewable power, Statkraft and chemical company INEOS Inovyn at Rafnes in Bamble have signed two new long-term power agreements....
Statkraft og Copenha
Statkraft og Copenhagen Infrastructure Partners går sammen om å utvikle 2,2 GW havvind i Irland
17 janv. 2023 01h00 HE | Statkraft AS
(Oslo 17. januar 2023) Statkraft går sammen med Copenhagen Infrastructure Partners' (CIP) for å bygge ut inntil 2,2 gigawatt havvind i Irland. Partnerskapet innebærer at CIP kjøper en 50 prosent...
Statkraft and Copenh
Statkraft and Copenhagen Infrastructure Partners team up to develop 2.2GW of offshore wind in Ireland
17 janv. 2023 01h00 HE | Statkraft AS
(17 January 2023) Statkraft has announced a major deal with Copenhagen Infrastructure Partners’ (CIP) fund Copenhagen Infrastructure IV K/S (CI IV) as part of its plans to develop up to 2.2 gigawatts...